Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Birur Chandra

Allergy & Immunology East Haven, CT Medical Doctor

NPI 1366484123 CMS profile 107476

317 Foxon Rd, East Haven, CT 06513

Open in the dashboard

General payments

$15,104

406 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Birur Chandra of East Haven, CT is reported in the CMS Open Payments database as having received $15,104 across 406 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,792 73
2024 General $3,031 78
2023 General $3,323 103
2022 General $2,405 80
2021 General $1,244 32
2020 General $23 1
2019 General $2,286 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Birur Chandra
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Birur Chandra were reported at $2,792. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Birur Chandra Allergy & Immunology median Middle half National median
2019 $2,286 $594 $163–$1,512 $163
2020 $23 $426 $106–$1,233 $114
2021 $1,244 $638 $157–$1,708 $132
2022 $2,405 $790 $205–$1,961 $149
2023 $3,323 $852 $220–$2,147 $160
2024 $3,031 $865 $203–$2,267 $164
2025 $2,792 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $4,923 83 payments
  2. GlaxoSmithKline, LLC. $3,147 132 payments
  3. Amgen Inc. $857 27 payments
  4. Novartis Pharmaceuticals Corporation $701 32 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $665 14 payments
  6. Regeneron Healthcare Solutions, Inc. $627 15 payments
  7. Merck Sharp & Dohme Corporation $603 10 payments
  8. Genzyme Corporation $586 13 payments
  9. Genentech USA, Inc. $504 19 payments
  10. Novo Nordisk Inc $350 3 payments
  11. Other $2,140 58 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,013 404 payments
  2. Education $91 2 payments
Products named General payments · program years 2019–2025
  1. FASENRA $1,817 33 payments
  2. NUCALA $1,571 80 payments
  3. TEZSPIRE Respiratory $1,388 24 payments
  4. BREZTRI $1,058 15 payments
  5. TRELEGY ELLIPTA $1,015 45 payments
  6. AIRSUPRA $762 11 payments
  7. TEZSPIRE Inflammation $750 26 payments
  8. DUPIXENT Immunology $675 14 payments
  9. STEGLATRO $588 9 payments
  10. DUPIXENT Inflammation And Immunology $578 13 payments
  11. Other $5,247 158 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

92

Median for Allergy/ Immunology: 449

Drug cost

$1,422

Median for Allergy/ Immunology: $169,700

Branded share of claims

21.7%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Albuterol Sulfate Hfa Albuterol Sulfate Brand 20 $468
Ipratropium Bromide Generic 22 $422
Fluticasone Propionate Generic 28 $379
Levocetirizine Dihydrochloride Generic 22 $153

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $443
  • Amgen Inc. $116
$560 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $478
$478 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $302
$302 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $284
$284 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $272
$272 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

406 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record